Flexion Therapeutics

Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for musculoskeletal conditions, particularly osteoarthritis (OA). The company offers ZILRETTA, an intra-articular injection specifically designed to manage knee pain associated with OA in the United States. In addition to ZILRETTA, Flexion is developing two notable product candidates: FX201, a gene therapy aimed at producing an anti-inflammatory protein to alleviate OA pain, and FX301, which is designed to inhibit NaV1.7 for managing post-operative pain. Founded in 2007 and headquartered in Burlington, Massachusetts, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates, sharing expertise and risk to enhance the development of innovative therapies for patients.